The image shows the recombinant antibody (FluorAbody®) produced by engineering SuperFolder GFP (sfGFP) with the variable heavy (VH) and variable light (VL) domains of the Herceptin antibody developed as a breast cancer therapeutic by Genentech. The anti-Her2 specific FluorAbodies are now being made available with cerulean, sfGFP, and red fluorescent protein (RFP) to the Life-Sciences research community. The reagents have been demonstrated to be Her2 specific with very low background staining compared to fluorochrome-labeled antibodies. Sandia Biotech is now developing a library of FluorAbodies for use in cancer diagnostics. Sandia Biotech's FluorAbodies have been shown to have much lower non-specifics than the fluorochrome-labeled antibodies. The increased performance has been shown in imaging applications with live and fixed cells and no-wash flow cytometry assays. Please try them and then let us know your results.